Why Viral Load Can Be Detectable Despite Perfect Adherence
Webinar on March 22 that will provide an update on new research into cases in which the HIV reservoir generates detectable viral load that cannot be suppressed by antiretroviral therapy.
CROI 2023 Tuberculosis Research Round Up
Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI).
2022 Report on TB Research Funding Trends
For the first time in history, funding for tuberculosis (TB) research and development (R&D) hit a billion dollars worldwide in 2021.
TAGline November 2022
This year’s edition of TAGline commemorates TAG’s 30th anniversary, and these articles explore TAG’s work over the years: what we've accomplished, what we've learned, the continuing obstacles to progress, and what comes next.
The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation
As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing vast civil society networks, and people living with and affected by malaria, HIV, tuberculosis, and the hepatitis C virus (HCV) across the world, we welcome the efforts leading to the development of an investigational long-acting injectable (LAI) formulation of ivermectin to fight malaria transmission, mdc-STM currently in preclinical stage, and developed by MedinCell.
Toward an Actionable and Rigorous United States Monkeypox Research Agenda
On September 14, 2022, a coalition of activists, researchers, and public health professionals sent the following letter to the White House MPX Coordinators, OSTP, CDC, and NIH/NIAID asking for a coordinated and adequately funded comprehensive Federal research effort to contain,…
Pathways Forward to End HIV: How HIV Cure Research is Helping to Advance HIV Vaccine Research
On September 20, please join Treatment Action Group, Dr. Shelly Karuna, and Dr. Karine Dubé for a webinar on the next generation of bnAbs trial design and ethics related to ATIs in HIV vaccine and cure research.
CROI 2022 TB Round Up
Treatment Action Group welcomes the tuberculosis (TB) data reported at the 2022 Conference on Retroviruses and Opportunistic Infections (CROI). This is a summary of major findings — and TAG’s take on them.
European Commitments to TB R&D Investments: Promises Made to Be Broken?
In this brief, TAG outlines the pathway the EU can take to scale up support for TB R&D, and advance the many European-sponsored TB vaccine candidates currently in the development pipeline.
2021 Report on TB Research Funding Trends
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2020 and analyzes trends in funding since 2005.